Compare Incyte Corporation (INCY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lowe`s Companies Inc — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while Lowe`s Companies Inc trades at $188.88 (market cap $105.96B). The key difference: Lowe`s Companies Inc is far larger — about 4.6× Incyte Corporation's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Lowe`s Companies Inc for 98 Days on average.
| INCY | LOW | |
|---|---|---|
Market Cap | $22.85B | $105.96B |
Volume | 1,927,029 | 4,039,547 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $287.39 |
52-Week Low | $83.80 | $179.50 |
Typical Hold Time | 33 Days | 98 Days |
Enterprise Value | $18.35B | $144.81B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Lowe's (LOW) trades at $181.54, down 1.17% on the day, with a bearish technical signal and recent price weakness amid a slowing home improvement market. The company has beaten earnings estimates for the last three quarters, with a P/E of 15.96 and net income margin of 7.35%. Recent news highlights drone delivery tests with DoorDash and Alphabet, while cash flow improved in 2025 but is projected to decline in 2026.
The stock offers value with a consensus price target of $244.09, implying 34% upside, supported by a 60.79% buy rating from analysts. Risks include high debt levels, competitive pressure from Home Depot, and sensitivity to housing market trends. The current technical setup suggests near-term support at $179, with potential for a rebound if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
